<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002047</url>
  </required_header>
  <id_info>
    <org_study_id>014H</org_study_id>
    <secondary_id>27433-19</secondary_id>
    <nct_id>NCT00002047</nct_id>
  </id_info>
  <brief_title>Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure</brief_title>
  <official_title>Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerance, and pharmacokinetics of Retrovir (AZT) administration in
      HIV-infected patients in renal failure receiving maintenance hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>Kidney Failure, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  A positive HIV antibody test (ELISA confirmed by Western blot).

          -  Chronic renal failure managed by a stable hemodialysis regimen.

          -  Acceptable hepatic function defined by specified lab values.

          -  Life expectancy &gt; 6 months.

          -  Enrollment is limited to 9 chronic hemodialysis patients and 9 Continuous Ambulatory
             Peritoneal Dialysis (CAPD) patients. These patients must be stable in their ESRD
             treatment regimen before entry.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following are excluded:

          -  Active, serious opportunistic infections at the time of study entry.

          -  Fever &gt; 100 degrees F at study entry.

          -  Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks
             duration with = or &gt; 6 loose stools per day accompanied by significant weight loss).

        Patients with the following are excluded:

          -  Active, serious opportunistic infections at the time of study entry.

          -  Fever &gt; 100 degrees F at study entry.

          -  Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks
             duration with = or &gt; 6 loose stools per day accompanied by significant weight loss).

        Prior Medication:

        Excluded within 2 weeks of study entry:

        - Any other experimental therapy. Drugs which cause significant bone marrow suppression.
        Rifampin or rifampin derivatives. Cytolytic chemotherapy. Drugs which cause significant
        hepatotoxicity.

        Excluded within 4 weeks of study entry:

        - Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin 2.

        Excluded within 8 weeks of study entry:

        - Other antiretroviral agents (e.g., zidovudine [AZT], suramin, ribavirin, HPA-23,
        foscarnet, dextran sulfate, disulfiram, ddA/ddC, or dideoxycytidine).

        Active drug or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Maryland at Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 1990</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Renal Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

